Citigroup’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,078
| Closed | -$889 | – | 5792 |
|
|
2025
Q1 | $889 | Buy |
+1,078
| New | +$1.04K | ﹤0.01% | 5372 |
|
|
2024
Q3 | – | Sell |
-724
| Closed | -$898 | – | 5746 |
|
|
2024
Q2 | $898 | Buy |
724
+324
| +81% | +$330 | ﹤0.01% | 5385 |
|
|
2024
Q1 | $520 | Hold |
400
| – | – | ﹤0.01% | 5457 |
|
|
2023
Q4 | $500 | Sell |
400
-31
| -7% | -$34 | ﹤0.01% | 5500 |
|
|
2023
Q3 | $560 | Hold |
431
| – | – | ﹤0.01% | 5188 |
|
|
2023
Q2 | $741 | Buy |
+431
| New | +$684 | ﹤0.01% | 5354 |
|
|
2023
Q1 | – | Sell |
-864
| Closed | -$1.4K | – | 5693 |
|
|
2022
Q4 | $1.4K | Sell |
864
-306
| -26% | -$704 | ﹤0.01% | 5342 |
|
|
2022
Q3 | $4K | Sell |
1,170
-2,479
| -68% | -$11.2K | ﹤0.01% | 5307 |
|
|
2022
Q2 | $13K | Sell |
3,649
-15,725
| -81% | -$71.3K | ﹤0.01% | 5234 |
|
|
2022
Q1 | $140K | Sell |
19,374
-50,151
| -72% | -$428K | ﹤0.01% | 4263 |
|
|
2021
Q4 | $945K | Buy |
69,525
+64,479
| +1,278% | +$1.01M | ﹤0.01% | 3318 |
|
|
2021
Q3 | $106K | Buy |
5,046
+2,890
| +134% | +$62.1K | ﹤0.01% | 4391 |
|
|
2021
Q2 | $52K | Buy |
2,156
+670
| +45% | +$17K | ﹤0.01% | 4808 |
|
|
2021
Q1 | $43K | Sell |
1,486
-1,274
| -46% | -$37.3K | ﹤0.01% | 4782 |
|
|
2020
Q4 | $82K | Buy |
+2,760
| New | +$86.6K | ﹤0.01% | 5698 |
|
Citigroup's KRON Position: Q2 2025 in Review
Citigroup sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 1,078 shares — an estimated $889 sold.
Citigroup first reported a position in KRON in Q4 2020 and held it in 15 quarters. The position peaked at $945K in Q4 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Citigroup reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Citigroup sold 1,078 Kronos Bio shares in Q2 2025, an estimated $889.
- Citigroup first reported a position in Kronos Bio in Q4 2020 and held it in 15 quarters.
- Citigroup's Kronos Bio position peaked at $945K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.